Welcome to our dedicated page for Nascent Biotech news (Ticker: NBIO), a resource for investors and traders seeking the latest updates and insights on Nascent Biotech stock.
Nascent Biotech, Inc. (NBIO) delivers innovative immunotherapy solutions through monoclonal antibody development for challenging cancers. This news hub provides investors and industry professionals with essential updates on clinical milestones, regulatory developments, and strategic partnerships.
Access real-time information about Phase I/II trial progress, drug delivery innovations, and collaborative research initiatives. Our curated collection features:
• Clinical trial results for brain and pancreatic cancer treatments
• Strategic collaborations with drug delivery specialists
• Regulatory updates and compliance announcements
• Research breakthroughs in antibody-based therapies
Bookmark this page for streamlined access to verified NBIO developments, enabling informed analysis of this clinical-stage biotech's progress in oncology innovation.
Nascent Biotech (OTCQB:NBIO) has received a notification from OTC Markets Group due to failing to file its Q3 2024 Form 10-Q on time. As a consequence, the company's stock has been moved from regular OTC Markets platforms to the 'Expert Market.' The company is actively working with auditors and legal advisors to complete the delayed filing and return to compliance with OTC Markets' listing requirements.
CEO Sean Carrick stated the company is committed to resolving the situation promptly and maintaining transparency. Once the filing requirements are met, NBIO expects its stock to resume normal quotation on OTC Markets' trading platforms.
Nascent Biotech (OTCQB:NBIO) presented at the Emerging Growth Conference on July 18, 2024, highlighting its progress in developing Pritumumab (PTB), a monoclonal antibody targeting various cancer types. CEO Sean Carrick discussed:
1. PTB's successful Phase I results and safety profile
2. Plans for Phase II trials focusing on brain cancer, with potential expansion to pancreatic and colorectal cancers
3. Timeline for manufacturing completion by year-end and Phase II trials starting in Q1 2025
4. The company's de-risked investment profile and need for funding to advance clinical trials
Nascent aims to begin expanded access trials for digestive cancers in Q2 2025, leveraging PTB's potential across multiple cancer types.
FAQ
What is the current stock price of Nascent Biotech (NBIO)?
What is the market cap of Nascent Biotech (NBIO)?
